Table 2.
Adverse events noted in charts of 38 patients using HyQvia in a clinical practice setting
| All (N = 38) n (%) | Discontinueda | |||
|---|---|---|---|---|
| No (N = 23) n (%) | Yes (N = 15) n (%) | P valueb | ||
| Patients with at least 1 AE | 29 (76.3) | 15 (65.2) | 14 (93.3) | 0.0501 |
| Local AEs | 23 (60.5) | 13 (56.5) | 10 (66.7) | 0.3897 |
| Erythema | 16 (42.1) | 12 (52.2) | 4 (26.7) | |
| Pain/burning during max rate infusion | 7 (18.4) | 5 (21.7) | 2 (13.3) | |
| Itching | 6 (15.8) | 2 (8.7) | 4 (26.7) | |
| Excessive swelling | 5 (13.2) | 2 (8.7) | 3 (20.0) | |
| Pain at site | 5 (13.2) | 3 (13.0) | 2 (13.3) | |
| Discomfort | 3 (7.9) | 2 (8.7) | 1 (6.7) | |
| Pain/burning during rate ramp-up | 2 (5.3) | 0 (0.0) | 2 (13.3) | |
| Pain/burning during hyaluronidase infusion | 2 (5.3) | 0 (0.0) | 2 (13.3) | |
| Continual burning | 2 (5.3) | 2 (8.7) | 0 (0.0) | |
| Leakage | 1 (2.6) | 0 (0.0) | 1 (6.7) | |
| Rash | 1 (2.6) | 0 (0.0) | 1 (6.7) | |
| Systemic AEs | 24 (63.2) | 11 (47.9) | 13 (86.7) | 0.0165 |
| Headache | 18 (47.4) | 9 (39.1) | 9 (60.0) | |
| Malaise | 10 (26.3) | 5 (21.7) | 5 (33.3) | |
| GI disorderc | 6 (15.8) | 3 (13.0) | 3 (20.0) | |
| Migraine | 3 (7.9) | 0 (0.0) | 3 (20.0) | |
| Fever | 5 (13.2) | 1 (4.3) | 4 (26.7) | |
| Body aches | 3 (7.9) | 2 (8.7) | 1 (6.7) | |
| Cough/sore throat/sinus infection | 2 (5.3) | 0 (0.0) | 2 (13.3) | |
| Rash (not infusion site) | 2 (5.3) | 1 (4.3) | 1 (6.7) | |
| Joint pain | 2 (5.3) | 1 (4.3) | 1 (6.7) | |
| Itch | 2 (5.3) | 1 (4.3) | 1 (6.7) | |
| Muscle weakness | 2 (5.3) | 0 (0.0) | 2 (13.3) | |
| Light sensitivity | 1 (2.6) | 0 (0.0) | 1 (6.7) | |
| Myalgias | 1 (2.6) | 0 (0.0) | 1 (6.7) | |
| Wheezing/chest tightness | 1 (2.6) | 0 (0.0) | 1 (6.7) | |
| Dehydration | 1 (2.6) | 0 (0.0) | 1 (6.7) | |
| Leakage | 1 (2.6) | 0 (0.0) | 1 (6.7) | |
AE adverse event, GI gastrointestinal
a Includes all reported AEs and does not imply that the listed AE was the reason for discontinuation in each row
b Within each row, comparison of percentage of patients in a given row who did not discontinue versus the percentage of patients who did discontinue (not the same as column percentages shown in the table; see text for relevant percentages). P values reflect one-tailed Fisher’s exact test
c For example, nausea, vomiting, diarrhea